Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:glycopyrrolate
|
| gptkbp:approves |
1960s
|
| gptkbp:brand |
gptkb:Robinul_Forte
gptkb:Robinul |
| gptkbp:class |
Anticholinergic agent
|
| gptkbp:clinical_trial |
Phase III trials
|
| gptkbp:contraindication |
gptkb:Myasthenia_gravis
Glaucoma Severe liver disease Severe renal impairment Urinary retention Severe ulcerative colitis |
| gptkbp:dissolved |
Soluble in water
Soluble in alcohol |
| gptkbp:dosage_form |
Oral tablet
Injectable solution |
| gptkbp:duration |
6 to 8 hours
|
| gptkbp:effective_date |
FDA approved
|
| gptkbp:formulation |
gptkb:tablet
Injection solution |
| https://www.w3.org/2000/01/rdf-schema#label |
Robinul
|
| gptkbp:indication |
Management of excessive salivation
Preoperative medication Treatment of peptic ulcers |
| gptkbp:ingredients |
gptkb:Glycopyrrolate
|
| gptkbp:interacts_with |
May interact with CNS depressants
May interact with antihistamines May interact with other anticholinergics |
| gptkbp:is_monitored_by |
Monitor for effectiveness
Monitor for signs of anticholinergic toxicity Monitor vital signs |
| gptkbp:is_used_for |
Reducing saliva production
|
| gptkbp:level |
7.65
|
| gptkbp:lifespan |
1.5 to 2 hours
|
| gptkbp:manager |
Oral
Injection |
| gptkbp:manufacturer |
Various manufacturers
|
| gptkbp:pharmacokinetics |
Metabolized in the liver
Excreted in urine Rapid absorption |
| gptkbp:premiered_on |
30 minutes to 1 hour
|
| gptkbp:products |
gptkb:Atropine
gptkb:Scopolamine |
| gptkbp:requires |
Prescription only
|
| gptkbp:side_effect |
gptkb:Tachycardia
gptkb:Nausea Allergic reactions Dizziness Constipation Blurred vision Dry mouth Urinary retention Confusion in elderly patients |
| gptkbp:social_structure |
C19 H26 Br N
|
| gptkbp:storage |
Store at room temperature
Protect from light |
| gptkbp:traded_on |
gptkb:Robinul
|
| gptkbp:weight |
368.33 g/mol
|